<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194892</url>
  </required_header>
  <id_info>
    <org_study_id>17299</org_study_id>
    <secondary_id>J1L-AM-JZGG</secondary_id>
    <secondary_id>AM0010-803</secondary_id>
    <nct_id>NCT04194892</nct_id>
  </id_info>
  <brief_title>A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants</brief_title>
  <acronym>Willow 3</acronym>
  <official_title>An Open Label, Randomized, Single Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics of Pre-filled Syringe Versus Vial Formulations of AM0010 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and
      how long it takes the body to remove it, when given as a solution formulation via a prefilled
      syringe (PFS) versus from a vial drawn into a conventional syringe. Information about side
      effects will be collected. The study is open to healthy participants. Total participant
      duration in trial is approximately 42 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">March 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 14, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK): Maximum Drug Concentration (Cmax) of Pegilodecakin</measure>
    <time_frame>Predose through approximately 14 days postdose</time_frame>
    <description>Cmax of Pegilodecakin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time of Maximum Concentration (Tmax)</measure>
    <time_frame>Predose through approximately 14 days postdose</time_frame>
    <description>Tmax of Pegilodecakin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Serum Concentration Versus Time Curve (AUC)</measure>
    <time_frame>Predose through approximately 14 days postdose</time_frame>
    <description>AUC of Pegilodecakin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pegilodecakin Vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegilodecakin administered subcutaneously (SQ) in one of two study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegilodecakin Pre-filled syringe (PFS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegilodecakin administered SQ in one of two study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegilodecakin</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Pegilodecakin Pre-filled syringe (PFS)</arm_group_label>
    <arm_group_label>Pegilodecakin Vial</arm_group_label>
    <other_name>LY3500518</other_name>
    <other_name>AM0010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a body mass index (BMI) between 19.0 and 32.0 kilograms per meter squared
             (kg/mÂ²) at study screening

          -  Must be Human Immunodeficiency Virus (HIV) negative by HIV 1/0/2 testing.

          -  Must be Hepatitis B (HBV) surface antigen negative

          -  Must be Hepatitis C (HCV) antibody negative

          -  Females must have a negative serum pregnancy test

        Exclusion Criteria:

          -  Pregnant or lactating subjects

          -  Have previously participated in an investigational trial involving administration of
             any investigational compound within 30 days prior to the study dosing

          -  Current alcohol or substance abuse judged by the Investigator to potentially interfere
             with subject compliance

          -  Have smoked or used tobacco/nicotine products within 90 days prior to the study dosing

          -  Have been treated with systemic steroids, immunosuppressant therapies or
             chemotherapeutic agents within 3 months of study screening, or expected to receive
             these agents during the study (e.g., corticosteroids, immunoglobulins, and other
             immune- or cytokine-based therapies)

          -  Have been vaccinated within 90 days of study dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase 1 Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

